UNSPSC 41141934: Cardiac allograft gene expression profiling test system

In this classification, Cardiac allograft gene expression profiling test system connotes a device used to measure Cardiac allograft gene expression profiling levels. US FDA regulates Cardiac allograft gene expression profiling test system under 21 CFR 862.1163 and under FDA product code OJQ.

UNSPSC 41141934 Cardiac allograft gene expression profiling test system is a Commodity code that in practice covers forensic drug analysis reagents, reference materials, and laboratory testing equipment procured by state and local public-health and law-enforcement agencies. The recent opportunities tagged under this code show state and local governments buying immunological testing kits for substance screening, certified drug reference standards for forensic laboratories, and DNA-screening kits for state laboratory operations. While the code's nominal name references cardiac tissue analysis, the actual procurement activity centers on controlled-substance detection and forensic drug-analysis support rather than cardiac diagnostics. Issuing bodies include state departments of public safety and health services, county forensic laboratories, and state law-enforcement agencies. These are typically public-lab operations with established accreditation requirements (ISO/IEC 17025 compliance appears across multiple opportunities) and compliance obligations under state and federal regulatory frameworks.

The geographic spread of recent activity centers on Texas and Florida, with involvement from Illinois. Representative recent opportunities include the Texas Department of Public Safety's July 2026 IFB for immunological reagent kits for substance screening (response date July 23, 2026), Pinellas County, Florida's April 2026 Invitation to Quote for certified drug reference standards with ISO/IEC 17025 accreditation and purity assurance (response date April 23, 2026, $72,126.85 in total federal funding), and the Texas Health and Human Services Commission's January 2026 IFB for QIAxcel and QIAamp DNA screening kits (response date January 29, 2026, with historical similar-goods spending between $25,050.00 and $30,000.00 in fiscal 2025). The Pinellas County opportunity explicitly offers SBE preference with expedited consideration for SBEs submitting within the first five business days and a five-percent price preference thereafter. Response deadlines in these opportunities range from same-day posting to 14 days; pre-bid coordination and question-response windows are typical.